Aton Pharma Launches Extended Program for Preservative-Free Timoptic® in Ocudose®
August 27, 2009
Aton Pharma, Inc. has announced that it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC® in OCUDOSE®, the only preservative-free medication for glaucoma available in the United States. Aton acquired the marketing rights to the Timoptic product line from Merck & Co., Inc. in February.
Aton will support TIMOPTIC in OCUDOSE with ophthalmic journal advertising, a couponing program, direct mail promotion and a patient information website. The sales force will re-introduce TIMOPTIC in OCUDOSE to eye care professionals as well.
Aton conducted a survey of ophthalmologists and found that 97% of those surveyed felt that preservative-free glaucoma medications could enhance the comfort of glaucoma patients. Nine out of ten surveyed that there are not enough preservative-free glaucoma medications available while almost one-half did not know that any preservative-free glaucoma beta-blocker medications existed. The presence of a preservative-free glaucoma medication may have an impact in the treatment of patients with glaucoma and dry eyes or lid margin disease.
Read the press release.
You might also enjoy...
- Aton Pharma Acquires Marketing Rights to Preservative-Free Timolol Product Line from Merck
- IOPtima Reports Successful Long-Term Results in the Use of its Laser System for Treatment of Glaucoma
- What is the Role of Nutrigenomics in Eye Health?
- Does Delaying Drug Treatment of Patients With Ocular Hypertension Increase the Risk of Glaucoma?
- Xalatan, Lumigan or Travatan for Glaucoma?
Comments
Jump down to form below to submit your own comments
